For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
This kit is designed for the detection of binding between FCGR3B (CD16b) and human IgG Fc fragment using a homogeneous AlphaLISA assay (no wash steps). This assay can facilitate the design and development of antibody therapeutics by using a competition assay format.
The Fc-Gamma Receptors (FCGRs) are members of immunoglobulin superfamily and play a critical role in the function of therapeutic antibodies. FCGRs are divided into three classes Fc-Gamma Receptor 1 (CD64), FCGR1; Fc-Gamma Receptor 2 (CD32), FCGR2 and Fc-Gamma receptor 3 (CD16), FCGR3. FCGR3 is expressed as two distinct forms (FCGR3A and FCGR3B) encoded by two different highly homologous genes in a cell type specific manner. FCGR3 is a low/intermediate affinity receptor for polyvalent immune-complexed IgG. FcGR3B binds complexed or aggregated IgG and also monomeric IgG. Contrary to FCGR3A, FCGR3B is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. It may serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils.
AlphaLISA detection of FCGR3B and IgG Fc fragment binding uses IgG Fc AlphaLISA® Acceptor beads and Streptavidin-coated Donor beads to capture biotinylated human FCGR3B. Donor beads and Acceptor beads come into proximity through IgG Fc fragment binding to FCGR3B. Excitation of the Donor beads provokes the release of singlet oxygen that triggers a cascade of energy transfer reactions in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
|Product Brand Name||AlphaLISA|
|Shipping Condition||Blue Ice|
|Unit Size||5,000 Assay Points|
A variety of chemotherapeutic drugs with different modes of action have been developed and tested as potential therapies for colorectal cancer. Characterizing the effects of potential drugs with different modes of action is a key part of the process.
In this application note you will learn:
Therapeutic antibodies have proven to be effective and safe treatments for various diseases, and understanding the binding of therapeutic antibodies to Fc receptors provides insights into their mechanism of action (MOA), efficacy, and safety. During early drug development, as potential therapeutic antibodies are selected and engineered, changes in Fc receptor affinity can be indicative of changes in effector function and serum half-life.
In this application note, we demonstrate how AlphaLISA® biochemical Fc receptor binding assays provide easy, robust methods to measure the binding of potential therapeutic antibodies to human Fc receptor proteins.